Deals In Depth: September 2014
Merrimack licensed Baxter its Phase III pancreatic cancer candidate MM398 for $100 million up front and $620 million in pre-commercial milestones; Merck KGAA added life sciences products in its $16.7 billion acquisition of Sigma-Aldrich. Biopharma and device financing were both up from the previous month.
You may also be interested in...
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.